¿Alguna vez te has preguntado de dónde proceden los átomos de oro de un anillo, el hierro de tu sangre o el carbono que conforma cada célula de tu cuerpo? La respuesta no se encuentra en la Tierra, sino en el corazón de estrellas extintas hace miles de millones de …
Del interior de las estrellas al Nobel de Física: la vida de William Alfred Fowler Read More »
Durante más de un siglo, la representación del color de los dinosaurios perteneció exclusivamente al terreno del arte y la especulación. Sin embargo, a partir de 2008, la paleontología dio un salto cuantitativo al demostrar que los pigmentos y la estructura microsc …
A career setback can teach you something useful—or teach you the wrong lesson. Executive coach Angela Justice explains how one difficult experience can quietly shape the choices that follow.
La Vanguardia de Kepler era una aguja de grafeno y titanio que perforaba el vacío absoluto hacia Gliese 667 Cc. En su interior, el silencio era casi total, salvo por el zumbido casi imperceptible de los reactores de fusión y el siseo del soporte vital. El modelo era sencillo, robusto y …
El Eco de los Siglos (Víctor Arenas) (Relato de CF) Read More »
Biotech crossover rounds could top $4.22 billion across about 28 rounds this year, PitchBook forecasts.
Steady stream of crossover rounds stock biotech’s IPO pipeline Read More »
As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.
Beyond China: Five other overseas destinations for biopharma dollars Read More »
CEO Robert Ford has said the atrial fibrillation treatment, along with the company’s Volt PFA device, is expected to help Abbott regain market share in electrophysiology.
Abbott wins FDA approval for dual-energy ablation catheter Read More »
Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.
Boston Scientific unlikely to meet guidance due to cyberattack Read More »
Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, ‘significantly exceeded expectations’ in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage study.
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data Read More »
After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’ Read More »
